Phage therapy for ventilator-associated pneumonia from drug-resistant bacteria
Part of Infections, Lungs & breathing clinical trials.
This trial tests a treatment that uses special viruses (called phages) to kill antibiotic-resistant bacteria causing pneumonia in people on ventilators. If you're eligible, this new approach might help fight the infection when standard antibiotics aren't working well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have pneumonia that started while on a ventilator (breathing machine).
- The pneumonia must be caused by one of these bacteria: Klebsiella pneumoniae, Acinetobacter baumannii, or Pseudomonas aeruginosa, and it must be resistant to many antibiotics.
- You must be between 18 and 85 years old.
- You must not be pregnant or breastfeeding.
- You must be stable enough to participate (not needing very high oxygen or very high ventilator pressure, and not having very unstable blood pressure).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adjusting antibiotics early, based on test results, can improve treatment for patients with severe pneumonia who are on a breathing machine in the intensive care unit. It aims to make antibiotic use more effective and reduce side effects.
This trial tests whether breathing in special viruses (called phages) that attack the Pseudomonas bacteria can help clear a serious lung infection in patients on ventilators. The treatment is added to standard antibiotics and may help fight the infection better.
This trial tests whether using a rapid test to find the exact bacteria causing your pneumonia can help doctors choose the right antibiotics faster, which might improve your recovery. The study compares this approach to usual care in patients on ventilators.
This trial tests an “antibiotic stewardship” approach—choosing and adjusting antibiotics in a smarter way—for a first episode of pneumonia in patients on a breathing machine. It may help ensure the right antibiotics are used at the right time, while avoiding unnecessary or overly broad treatment.
This study tests a new treatment that combines regular antibiotics with a special virus that attacks bacteria (called a phage) to fight lung infections that do not respond to standard antibiotics. It aims to see if this combination is safe and might help people with cystic fibrosis who have stubborn lung infections.
This trial tests whether giving preventive antibiotics to adults on breathing machines lowers the risk of developing pneumonia during ventilation. It is a double-blind study, meaning neither you nor your doctor will know if you receive the antibiotic or a placebo.
Hear when a new VAP - Ventilator Associated Pneumonia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.